{"organizations": [], "uuid": "1a29882897dd742c4204978711c3a47a74cf4d7d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "https://images.wsj.net/im-3605/social", "site_section": "http://www.wsj.com/xml/rss/3_7014.xml", "section_title": "WSJ.com: US Business", "url": "https://www.wsj.com/articles/regeneron-and-sanofi-plan-to-cut-cholesterol-drug-price-in-exchange-for-wider-coverage-1520690400", "country": "US", "domain_rank": 387, "title": "Regeneron and Sanofi Plan to Cut Cholesterol Drug Price in Exchange for Wider Coverage", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-10T16:00:00.000+02:00", "replies_count": 0, "uuid": "1a29882897dd742c4204978711c3a47a74cf4d7d"}, "author": "Joseph Walker", "url": "https://www.wsj.com/articles/regeneron-and-sanofi-plan-to-cut-cholesterol-drug-price-in-exchange-for-wider-coverage-1520690400", "ord_in_thread": 0, "title": "Regeneron and Sanofi Plan to Cut Cholesterol Drug Price in Exchange for Wider Coverage", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "regeneron", "sentiment": "negative"}, {"name": "sanofi", "sentiment": "negative"}, {"name": "sanofi sa", "sentiment": "none"}, {"name": "regeneron pharmaceuticals inc.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "The makers of an expensive cholesterol-lowering drug plan to offer discounts of up to 69% in exchange for insurers and pharmacy-benefit managers expanding their coverage of the medicine to more patients.\nRegeneron Pharmaceuticals Inc. and Sanofi SA said they will seek to renegotiate their contracts with insurers by offering rebates and discounts for the drug, called Praluent, that would bring its U.S. net price within a range of $4,500 to $8,000 annually per patient, down from its list price of $14,600.\n... To Read the Full Story Subscribe Sign In", "external_links": [], "published": "2018-03-10T16:00:00.000+02:00", "crawled": "2018-03-10T21:12:24.034+02:00", "highlightTitle": ""}